AT525085T - Treatment of neoplasms with neurotoxin - Google Patents

Treatment of neoplasms with neurotoxin

Info

Publication number
AT525085T
AT525085T AT05814023T AT05814023T AT525085T AT 525085 T AT525085 T AT 525085T AT 05814023 T AT05814023 T AT 05814023T AT 05814023 T AT05814023 T AT 05814023T AT 525085 T AT525085 T AT 525085T
Authority
AT
Austria
Prior art keywords
neurotoxin
neoplasms
treatment
Prior art date
Application number
AT05814023T
Other languages
German (de)
Inventor
Christopher Shaari
Original Assignee
Toxcure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US61244304P priority Critical
Application filed by Toxcure Inc filed Critical Toxcure Inc
Priority to PCT/US2005/033982 priority patent/WO2006034404A2/en
Publication of AT525085T publication Critical patent/AT525085T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
AT05814023T 2004-09-23 2005-09-23 Treatment of neoplasms with neurotoxin AT525085T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US61244304P true 2004-09-23 2004-09-23
PCT/US2005/033982 WO2006034404A2 (en) 2004-09-23 2005-09-23 Treating neoplasms with neurotoxin

Publications (1)

Publication Number Publication Date
AT525085T true AT525085T (en) 2011-10-15

Family

ID=36090674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814023T AT525085T (en) 2004-09-23 2005-09-23 Treatment of neoplasms with neurotoxin

Country Status (8)

Country Link
US (3) US7709440B2 (en)
EP (4) EP2985034A1 (en)
AT (1) AT525085T (en)
CA (2) CA2586793C (en)
DK (2) DK2168594T3 (en)
ES (3) ES2555856T3 (en)
PT (2) PT2168594E (en)
WO (1) WO2006034404A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153734D0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
US20090232849A1 (en) * 2005-03-03 2009-09-17 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
AU2009319732B2 (en) * 2008-11-26 2013-09-05 Toxcure, Inc. Treating neoplasms with neurotoxin
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
WO2013153191A1 (en) 2012-04-13 2013-10-17 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (ii)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9473152B2 (en) * 2013-11-08 2016-10-18 Taiwan Semiconductor Manufacturing Company, Ltd. Coupling structure for inductive device
EP3226792A4 (en) * 2014-12-04 2018-07-11 Autonomix Medical, Inc. Systems and methods for regulating organ and/or tumor growth rates, function, and/or development
WO2018039090A1 (en) * 2016-08-20 2018-03-01 Gregg John Maicolm Hall Methods of use & compositions of ibd, ibs, & antineoplastic microbial therapeutics

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194025T3 (en) * 1993-06-10 2003-11-16 Allergan Inc Multiple botulinum toxins for treating neuromuscular disorders and conditions.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
WO2002009743A1 (en) 2000-08-02 2002-02-07 Allergan Sales, Inc. Method for treating a neoplasm
US20060134140A1 (en) * 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
DE10228103A1 (en) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungicidal active ingredient combinations
US20060153876A1 (en) 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US20090232849A1 (en) 2005-03-03 2009-09-17 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin

Also Published As

Publication number Publication date
US20090028972A1 (en) 2009-01-29
WO2006034404A3 (en) 2006-08-10
ES2548152T3 (en) 2015-10-14
DK1802339T3 (en) 2011-10-24
EP2168594A1 (en) 2010-03-31
EP2168594B1 (en) 2015-04-29
EP2298339B1 (en) 2015-07-15
CA2586793A1 (en) 2006-03-30
ES2555856T3 (en) 2016-01-11
US8435951B2 (en) 2013-05-07
PT2168594E (en) 2015-09-15
EP1802339A2 (en) 2007-07-04
EP1802339A4 (en) 2008-03-05
WO2006034404A2 (en) 2006-03-30
DK2168594T3 (en) 2015-08-03
US7709440B2 (en) 2010-05-04
PT1802339E (en) 2011-12-15
US20130236497A1 (en) 2013-09-12
EP2985034A1 (en) 2016-02-17
CA2586793C (en) 2015-03-24
EP1802339B1 (en) 2011-09-21
EP2298339A1 (en) 2011-03-23
CA2875562A1 (en) 2006-03-30
US20100209456A1 (en) 2010-08-19
ES2373963T3 (en) 2012-02-10

Similar Documents

Publication Publication Date Title
DK1885411T3 (en) injecting
DK1888147T3 (en) injecting
DK1856042T3 (en) Substituted gamma-lactams as therapeutic agents
DK1888595T3 (en) Spiro-oxindole compounds and their applications as therapeutic agents
DK1715903T3 (en) injecting
DK1755713T3 (en) injecting
DK1755706T3 (en) injecting
DK1755709T3 (en) injecting
DK1755710T3 (en) injecting
DK1755708T3 (en) injecting
DK1753490T3 (en) injecting
DK1802579T3 (en) Derivatives of 3-arylaminopyridine
DK2366415T3 (en) injecting
DE602006016150D1 (en) Prevention of diseases at kaiserschnitt-babies
AT502153T (en) Drier
DE602005011656D1 (en) Method for the treatment of thick-cancer with botulinum neurotoxin
DE602005020758D1 (en) Proof of sleep
AT482722T (en) Therapeutic use of anti-cs1 antibodies
DE602006008280D1 (en) Improvements related to skin associations
AT512663T (en) Combination for the treatment of diseases with cell proliferation
AT479673T (en) Hemmer of the reproduction of human immunefekt virus
DK1720866T3 (en) Course of action
AT433984T (en) Compounds and method for the treatment of dyslipidemia
AT553198T (en) Treatment of cancer by the combined inhibition of proteasome and telomerase activities
DK1706112T3 (en) Methods of treating an inflammator-related disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1802339

Country of ref document: EP